Published in J Neural Transm Suppl on January 01, 1994
NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol (2008) 2.13
A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry (2012) 1.58
Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol (2007) 1.34
Are we studying and treating schizophrenia correctly? Schizophr Res (2011) 1.19
A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) (2006) 1.18
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta (2008) 1.08
Pharmacodynamics of memantine: an update. Curr Neuropharmacol (2008) 1.03
Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers. Psychopharmacology (Berl) (2007) 1.01
The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives. Chem Rev (2013) 0.98
Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol (1996) 0.98
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther (2009) 0.98
Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics (2011) 0.97
Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. Neuropharmacology (2009) 0.94
Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393. Br J Pharmacol (1999) 0.92
Bipolar disorder: involvement of signaling cascades and AMPA receptor trafficking at synapses. Neuron Glia Biol (2004) 0.92
A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders. Psychol Res Behav Manag (2015) 0.89
The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. Pharmacol Rev (2016) 0.86
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice. J Neural Transm (Vienna) (2001) 0.84
Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol (2004) 0.82
Pharmacological tests of hypotheses for acquired pendular nystagmus. Ann N Y Acad Sci (2011) 0.81
Towards medication-enhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol (2012) 0.80
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice. Psychopharmacology (Berl) (2006) 0.80
Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. J Neural Transm (Vienna) (2011) 0.80
A Validated Stability-indicating Reverse Phase HPLC Assay Method for the Determination of Memantine Hydrochloride Drug Substance with UV-Detection Using Precolumn Derivatization Technique. Anal Chem Insights (2010) 0.77
6-Hydroxydopamine lesion of locus coeruleus and the antiparkinsonian potential of NMDA-receptor antagonists in rats. J Neural Transm (Vienna) (1997) 0.77
Amantadine: a review of use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry (2013) 0.77
Catecholaminergic based therapies for functional recovery after TBI. Brain Res (2015) 0.76
Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy. SAGE Open Med Case Rep (2017) 0.75
Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of Stroke. J Cent Nerv Syst Dis (2017) 0.75
Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol (1996) 0.75
The drug treatment of delayed ejaculation. Transl Androl Urol (2016) 0.75
"Herbal seizures" - atypical symptoms after ibogaine intoxication: a case report. J Med Case Rep (2015) 0.75
Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine. J Neural Transm (Vienna) (2016) 0.75
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
Anterior opercular cortex lesions cause dissociated lower cranial nerve palsies and anarthria but no aphasia: Foix-Chavany-Marie syndrome and "automatic voluntary dissociation" revisited. J Neurol (1993) 3.70
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene (2006) 2.82
Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med (2003) 2.60
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res (2001) 2.26
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med (1995) 2.08
CNTF and endogenous psychoses? Nat Genet (1996) 2.02
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Letter: Unusual cardiac and neurological reactions to narcotics. Lancet (1973) 1.90
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science (2000) 1.77
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Turnover of protein-bound phosphorylserine in membrane preparations from ox brain catalysed by intrinsic kinase and phosphatase activity. Biochem J (1971) 1.68
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol (2010) 1.63
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Protein kinase activity in membrane preparations from ox brain. Stimulation of intrinsic activity by adenosine 3':5'-cyclic monophosphate. Biochem J (1973) 1.59
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. J Neurosci (1996) 1.56
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology (2005) 1.52
Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol (2003) 1.49
Short rib-polydactyly (SRP) syndromes, types Majewski and Saldino-Noonan. Z Kinderheilkd (1974) 1.48
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol (2002) 1.46
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol (1998) 1.45
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
Does clozapine cause neuroleptic malignant syndrome? J Clin Psychiatry (1993) 1.41
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40
[Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder]. Z Gastroenterol (2005) 1.40
MRI features of primary central nervous system lymphomas at presentation. Neurology (2001) 1.40
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Elevated levels of fibronectin in the CSF: what do they signify? J Neurol Sci (1992) 1.38
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology (2004) 1.36
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol (2001) 1.33
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett (1998) 1.32
Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res (1999) 1.31
Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech (2001) 1.30
BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry (1999) 1.29
Stimulation by cyclic AMP of intrinsic protein kinase activity in ox brain membrane preparations. Nature (1970) 1.29
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol (1999) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26
Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol (1995) 1.26
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol (1991) 1.26
Serotonin, noradrenaline, dopamine metabolites in transcendental meditation-technique. J Neural Transm (1976) 1.26
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene (2003) 1.26
Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene (2000) 1.26
Comparing explorative saccade and flicker training in hemianopia: a randomized controlled study. Neurology (2009) 1.25
Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res (1999) 1.24
Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect (1995) 1.23
Breaking symmetry: the marine environment, prey size, and the evolution of asymmetry in cetacean skulls. Anat Rec (Hoboken) (2007) 1.22
Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem (1997) 1.21
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm (Vienna) (2003) 1.18
Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology (1997) 1.17
Large scale preparation of a crude membrane fraction from ox brain. J Neurochem (1969) 1.16
Violence and mental illness. Br Med J (Clin Res Ed) (1984) 1.16
Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc Natl Acad Sci U S A (1999) 1.15
The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord (1993) 1.15
Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci (2001) 1.14
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene (2009) 1.13
HSV-2 sacral radiculitis (Elsberg syndrome). Neurology (2004) 1.12
Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br J Cancer (1999) 1.12
Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ (1999) 1.11
Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry (1997) 1.11
Molecular determinants of glioma cell migration and invasion. J Neurosurg (2001) 1.11
Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol (2005) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J Neurol (2000) 1.10
Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol (2001) 1.10